<!DOCTYPE html>
<html lang="en" xml:lang="en">
<head>

  <meta charset="utf-8" />
  <meta http-equiv="X-UA-Compatible" content="IE=edge" />
  <title>Chapter 3 Revising MELD from calendar-time cross-sections with correction for selection bias | Organ allocation models in Eurotransplant</title>
  <meta name="description" content="This is the PhD thesis of H.C. de Ferrante" />
  <meta name="generator" content="bookdown 0.42 and GitBook 2.6.7" />

  <meta property="og:title" content="Chapter 3 Revising MELD from calendar-time cross-sections with correction for selection bias | Organ allocation models in Eurotransplant" />
  <meta property="og:type" content="book" />
  <meta property="og:image" content="/cover/thesis_cover.png" />
  <meta property="og:description" content="This is the PhD thesis of H.C. de Ferrante" />
  

  <meta name="twitter:card" content="summary" />
  <meta name="twitter:title" content="Chapter 3 Revising MELD from calendar-time cross-sections with correction for selection bias | Organ allocation models in Eurotransplant" />
  
  <meta name="twitter:description" content="This is the PhD thesis of H.C. de Ferrante" />
  <meta name="twitter:image" content="/cover/thesis_cover.png" />

<meta name="author" content="Hans Christiaan de Ferrante" />



  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <meta name="apple-mobile-web-app-capable" content="yes" />
  <meta name="apple-mobile-web-app-status-bar-style" content="black" />
  
  
<link rel="prev" href="CHprefaceliver.html"/>
<link rel="next" href="CHsexdisparity.html"/>
<script src="libs/jquery-3.6.0/jquery-3.6.0.min.js"></script>
<script src="https://cdn.jsdelivr.net/npm/fuse.js@6.4.6/dist/fuse.min.js"></script>
<link href="libs/gitbook-2.6.7/css/style.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-table.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-bookdown.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-highlight.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-search.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-fontsettings.css" rel="stylesheet" />
<link href="libs/gitbook-2.6.7/css/plugin-clipboard.css" rel="stylesheet" />








<link href="libs/anchor-sections-1.1.0/anchor-sections.css" rel="stylesheet" />
<link href="libs/anchor-sections-1.1.0/anchor-sections-hash.css" rel="stylesheet" />
<script src="libs/anchor-sections-1.1.0/anchor-sections.js"></script>
<script src="libs/kePrint-0.0.1/kePrint.js"></script>
<link href="libs/lightable-0.0.1/lightable.css" rel="stylesheet" />
<link href="libs/bsTable-3.3.7/bootstrapTable.min.css" rel="stylesheet" />
<script src="libs/bsTable-3.3.7/bootstrapTable.js"></script>



<style type="text/css">
  
  div.hanging-indent{margin-left: 1.5em; text-indent: -1.5em;}
</style>
<style type="text/css">
/* Used with Pandoc 2.11+ new --citeproc when CSL is used */
div.csl-bib-body { }
div.csl-entry {
  clear: both;
  margin-bottom: 0em;
}
.hanging div.csl-entry {
  margin-left:2em;
  text-indent:-2em;
}
div.csl-left-margin {
  min-width:2em;
  float:left;
}
div.csl-right-inline {
  margin-left:2em;
  padding-left:1em;
}
div.csl-indent {
  margin-left: 2em;
}
</style>

<link rel="stylesheet" href="style.css" type="text/css" />
</head>

<body>



  <div class="book without-animation with-summary font-size-2 font-family-1" data-basepath=".">

    <div class="book-summary">
      <nav role="navigation">

<ul class="summary">
<li class="chapter" data-level="" data-path="index.html"><a href="index.html"><i class="fa fa-check"></i>Preface</a></li>
<li class="chapter" data-level="" data-path="dankwoord.html"><a href="dankwoord.html"><i class="fa fa-check"></i>Dankwoord</a></li>
<li class="chapter" data-level="1" data-path="CHintroduction.html"><a href="CHintroduction.html"><i class="fa fa-check"></i><b>1</b> Introduction</a>
<ul>
<li class="chapter" data-level="1.1" data-path="CHintroduction.html"><a href="CHintroduction.html#eurotransplant"><i class="fa fa-check"></i><b>1.1</b> Eurotransplant</a></li>
<li class="chapter" data-level="1.2" data-path="CHintroduction.html"><a href="CHintroduction.html#objective-medical-criteria-for-organ-allocation"><i class="fa fa-check"></i><b>1.2</b> Objective medical criteria for organ allocation</a></li>
<li class="chapter" data-level="1.3" data-path="CHintroduction.html"><a href="CHintroduction.html#fairness-in-organ-allocation"><i class="fa fa-check"></i><b>1.3</b> Fairness in organ allocation</a></li>
<li class="chapter" data-level="1.4" data-path="CHintroduction.html"><a href="CHintroduction.html#challenges-in-improving-organ-allocation-systems"><i class="fa fa-check"></i><b>1.4</b> Challenges in improving organ allocation systems</a></li>
<li class="chapter" data-level="1.5" data-path="CHintroduction.html"><a href="CHintroduction.html#outline-of-this-thesis"><i class="fa fa-check"></i><b>1.5</b> Outline of this thesis</a></li>
</ul></li>
<li class="chapter" data-level="2" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html"><i class="fa fa-check"></i><b>2</b> Liver allocation in Eurotransplant</a>
<ul>
<li class="chapter" data-level="2.1" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#liver-allocation-prior-to-meld"><i class="fa fa-check"></i><b>2.1</b> Liver allocation prior to MELD</a></li>
<li class="chapter" data-level="2.2" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#meld-based-liver-allocation-in-the-united-states"><i class="fa fa-check"></i><b>2.2</b> MELD-based liver allocation in the United States</a></li>
<li class="chapter" data-level="2.3" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#meld-based-liver-allocation-in-eurotransplant"><i class="fa fa-check"></i><b>2.3</b> MELD-based liver allocation in Eurotransplant</a></li>
<li class="chapter" data-level="2.4" data-path="CHprefaceliver.html"><a href="CHprefaceliver.html#areas-for-improvement-in-meld-based-allocation-systems"><i class="fa fa-check"></i><b>2.4</b> Areas for improvement in MELD-based allocation systems</a></li>
</ul></li>
<li class="chapter" data-level="3" data-path="CHdynremeld.html"><a href="CHdynremeld.html"><i class="fa fa-check"></i><b>3</b> Revising MELD from calendar-time cross-sections with correction for selection bias</a>
<ul>
<li class="chapter" data-level="3.1" data-path="CHdynremeld.html"><a href="CHdynremeld.html#introduction"><i class="fa fa-check"></i><b>3.1</b> Introduction</a></li>
<li class="chapter" data-level="3.2" data-path="CHdynremeld.html"><a href="CHdynremeld.html#materials-and-methods"><i class="fa fa-check"></i><b>3.2</b> Materials and methods</a></li>
<li class="chapter" data-level="3.3" data-path="CHdynremeld.html"><a href="CHdynremeld.html#results"><i class="fa fa-check"></i><b>3.3</b> Results</a></li>
<li class="chapter" data-level="3.4" data-path="CHdynremeld.html"><a href="CHdynremeld.html#discussion"><i class="fa fa-check"></i><b>3.4</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="4" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html"><i class="fa fa-check"></i><b>4</b> Sex disparity in liver allocation within Eurotransplant</a>
<ul>
<li class="chapter" data-level="4.1" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#introduction-1"><i class="fa fa-check"></i><b>4.1</b> Introduction</a></li>
<li class="chapter" data-level="4.2" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#materials-and-methods-1"><i class="fa fa-check"></i><b>4.2</b> Materials and methods</a></li>
<li class="chapter" data-level="4.3" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#results-1"><i class="fa fa-check"></i><b>4.3</b> Results</a></li>
<li class="chapter" data-level="4.4" data-path="CHsexdisparity.html"><a href="CHsexdisparity.html#discussion-1"><i class="fa fa-check"></i><b>4.4</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="5" data-path="CHelassimulator.html"><a href="CHelassimulator.html"><i class="fa fa-check"></i><b>5</b> The ELAS simulator</a>
<ul>
<li class="chapter" data-level="5.1" data-path="CHelassimulator.html"><a href="CHelassimulator.html#introduction-2"><i class="fa fa-check"></i><b>5.1</b> Introduction</a></li>
<li class="chapter" data-level="5.2" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elassystem"><i class="fa fa-check"></i><b>5.2</b> The Eurotransplant Liver Allocation System (ELAS)</a></li>
<li class="chapter" data-level="5.3" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasdesign"><i class="fa fa-check"></i><b>5.3</b> The design of the ELAS simulator</a></li>
<li class="chapter" data-level="5.4" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasmodules"><i class="fa fa-check"></i><b>5.4</b> Modules of the ELAS simulator</a></li>
<li class="chapter" data-level="5.5" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasvv"><i class="fa fa-check"></i><b>5.5</b> Verification and validation</a></li>
<li class="chapter" data-level="5.6" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elascasestudies"><i class="fa fa-check"></i><b>5.6</b> Case studies: the impact of modifying ELAS rules</a></li>
<li class="chapter" data-level="5.7" data-path="CHelassimulator.html"><a href="CHelassimulator.html#sec:elasconclusion"><i class="fa fa-check"></i><b>5.7</b> Conclusions and discussion</a></li>
</ul></li>
<li class="chapter" data-level="6" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html"><i class="fa fa-check"></i><b>6</b> Kidney allocation in Eurotransplant</a>
<ul>
<li class="chapter" data-level="6.1" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html#hla-matching-versus-fairness"><i class="fa fa-check"></i><b>6.1</b> HLA matching versus fairness</a></li>
<li class="chapter" data-level="6.2" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html#kidney-allocation-programs-in-eurotransplant"><i class="fa fa-check"></i><b>6.2</b> Kidney allocation programs in Eurotransplant</a></li>
<li class="chapter" data-level="6.3" data-path="CHprefacekidney.html"><a href="CHprefacekidney.html#contemporary-challenges-in-kidney-allocation"><i class="fa fa-check"></i><b>6.3</b> Contemporary challenges in kidney allocation</a></li>
</ul></li>
<li class="chapter" data-level="7" data-path="CHvpra.html"><a href="CHvpra.html"><i class="fa fa-check"></i><b>7</b> Access to transplantation for immunized candidates</a>
<ul>
<li class="chapter" data-level="7.1" data-path="CHvpra.html"><a href="CHvpra.html#introduction-3"><i class="fa fa-check"></i><b>7.1</b> Introduction</a></li>
<li class="chapter" data-level="7.2" data-path="CHvpra.html"><a href="CHvpra.html#materials-and-methods-2"><i class="fa fa-check"></i><b>7.2</b> Materials and methods</a></li>
<li class="chapter" data-level="7.3" data-path="CHvpra.html"><a href="CHvpra.html#results-2"><i class="fa fa-check"></i><b>7.3</b> Results</a></li>
<li class="chapter" data-level="7.4" data-path="CHvpra.html"><a href="CHvpra.html#discussion-2"><i class="fa fa-check"></i><b>7.4</b> Discussion</a></li>
</ul></li>
<li class="chapter" data-level="8" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html"><i class="fa fa-check"></i><b>8</b> The ETKidney simulator</a>
<ul>
<li class="chapter" data-level="8.1" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#introduction-4"><i class="fa fa-check"></i><b>8.1</b> Introduction</a></li>
<li class="chapter" data-level="8.2" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneyalloc"><i class="fa fa-check"></i><b>8.2</b> The kidney allocation programs of Eurotransplant</a></li>
<li class="chapter" data-level="8.3" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneydesign"><i class="fa fa-check"></i><b>8.3</b> Purpose and design of the ETKidney Simulator</a></li>
<li class="chapter" data-level="8.4" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneymodules"><i class="fa fa-check"></i><b>8.4</b> Modules of the ETKidney simulator</a></li>
<li class="chapter" data-level="8.5" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneyvv"><i class="fa fa-check"></i><b>8.5</b> Verification and validation</a></li>
<li class="chapter" data-level="8.6" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneycasestudies"><i class="fa fa-check"></i><b>8.6</b> Case studies</a></li>
<li class="chapter" data-level="8.7" data-path="CHetkidneysimulator.html"><a href="CHetkidneysimulator.html#sec:etkidneydiscussion"><i class="fa fa-check"></i><b>8.7</b> Discussion and conclusion</a></li>
</ul></li>
<li class="chapter" data-level="9" data-path="CHdiscussion.html"><a href="CHdiscussion.html"><i class="fa fa-check"></i><b>9</b> The way forward</a>
<ul>
<li class="chapter" data-level="9.1" data-path="CHdiscussion.html"><a href="CHdiscussion.html#this-thesis-is-a-sharp-look-at-familiar-problems"><i class="fa fa-check"></i><b>9.1</b> This thesis is a sharp look at familiar problems</a></li>
<li class="chapter" data-level="9.2" data-path="CHdiscussion.html"><a href="CHdiscussion.html#we-need-to-look-beyond-survival-models-for-allocation"><i class="fa fa-check"></i><b>9.2</b> We need to look beyond survival models for allocation</a></li>
<li class="chapter" data-level="9.3" data-path="CHdiscussion.html"><a href="CHdiscussion.html#we-should-look-beyond-aggregate-outcomes"><i class="fa fa-check"></i><b>9.3</b> We should look beyond aggregate outcomes</a></li>
<li class="chapter" data-level="9.4" data-path="CHdiscussion.html"><a href="CHdiscussion.html#scientific-evidence-is-rarely-the-bottleneck"><i class="fa fa-check"></i><b>9.4</b> Scientific evidence is rarely the bottleneck</a></li>
<li class="chapter" data-level="9.5" data-path="CHdiscussion.html"><a href="CHdiscussion.html#the-chicken-and-egg-problem-in-allocation-development"><i class="fa fa-check"></i><b>9.5</b> The “chicken-and-egg” problem in allocation development</a></li>
<li class="chapter" data-level="9.6" data-path="CHdiscussion.html"><a href="CHdiscussion.html#we-need-more-constructive-dialogue"><i class="fa fa-check"></i><b>9.6</b> We need more constructive dialogue</a></li>
</ul></li>
<li class="appendix"><span><b>Appendix</b></span></li>
<li class="chapter" data-level="A" data-path="APPipcw.html"><a href="APPipcw.html"><i class="fa fa-check"></i><b>A</b> Inverse Probability Censoring Weights</a>
<ul>
<li class="chapter" data-level="" data-path="APPipcw.html"><a href="APPipcw.html#definition-of-ipcw-weights"><i class="fa fa-check"></i>Definition of IPCW weights</a></li>
</ul></li>
<li class="chapter" data-level="B" data-path="APPimputation.html"><a href="APPimputation.html"><i class="fa fa-check"></i><b>B</b> Completing the status updates streams for transplant recipients</a>
<ul>
<li class="chapter" data-level="B.1" data-path="APPimputation.html"><a href="APPimputation.html#step-1-and-2-construction-of-the-pseudo-observations"><i class="fa fa-check"></i><b>B.1</b> Step 1 and 2: Construction of the pseudo-observations</a></li>
<li class="chapter" data-level="B.2" data-path="APPimputation.html"><a href="APPimputation.html#step-3-fitting-a-model-for-the-mean-restricted-survival-time"><i class="fa fa-check"></i><b>B.2</b> Step 3: Fitting a model for the mean restricted survival time</a></li>
<li class="chapter" data-level="B.3" data-path="APPimputation.html"><a href="APPimputation.html#step-4-constructing-future-statuses"><i class="fa fa-check"></i><b>B.3</b> Step 4: Constructing future statuses</a></li>
<li class="chapter" data-level="B.4" data-path="APPimputation.html"><a href="APPimputation.html#step-4.2-matching-the-patient-to-a-particular-patient-in-the-risk-set"><i class="fa fa-check"></i><b>B.4</b> Step 4.2: Matching the patient to a particular patient in the risk set</a></li>
</ul></li>
<li class="chapter" data-level="" data-path="summary.html"><a href="summary.html"><i class="fa fa-check"></i>Summary</a></li>
<li class="chapter" data-level="" data-path="course-of-life.html"><a href="course-of-life.html"><i class="fa fa-check"></i>Course of Life</a></li>
<li class="chapter" data-level="" data-path="list-of-publications.html"><a href="list-of-publications.html"><i class="fa fa-check"></i>List of publications</a></li>
<li class="divider"></li>
<li><a href="https://github.com/rstudio/bookdown" target="blank">Published with bookdown</a></li>

</ul>

      </nav>
    </div>

    <div class="book-body">
      <div class="body-inner">
        <div class="book-header" role="navigation">
          <h1>
            <i class="fa fa-circle-o-notch fa-spin"></i><a href="./">Organ allocation models in Eurotransplant</a>
          </h1>
        </div>

        <div class="page-wrapper" tabindex="-1" role="main">
          <div class="page-inner">

            <section class="normal" id="section-">
<div id="CHdynremeld" class="section level1 hasAnchor" number="3">
<h1><span class="header-section-number">Chapter 3</span> Revising MELD from calendar-time cross-sections with correction for selection bias<a href="CHdynremeld.html#CHdynremeld" class="anchor-section" aria-label="Anchor link to header"></a></h1>
<p></p>
<hr />
<p>
An article based on this chapter has appeared in <em>BMC Medical Research Methodology</em>, de Ferrante, H.C., De Rosner-van Rosmalen M., Smeulders, B.M.L., Vogelaar, S., Spieksma, F.C.R., 2024, <a href="https://doi.org/10.1186/s12874-024-02176-8">10.1186/s12874-024-02176-8</a>,
<span class="citation"><a href="#ref-deFerranteDynremeld">[55]</a></span></p>
<p>
</p>
<p><p><strong>Abstract</strong></p>
</p>
<p>Eurotransplant allocates livers using the MELD score as originally proposed
by UNOS. Several studies have revised this UNOS-MELD score using retrospective
data on liver transplant candidates. The standard approach taken in such studies is to model 90-day
waiting list mortality from the time of listing, based on biomarkers reported at
listing, while censoring candidates at delisting or transplantation. This approach
ignores a candidate’s biomarkers that were reported after registration, and ignores informative
censoring by transplantation and delisting.</p>
<p>We study how MELD revision is affected by using calendar-time
cross-sections and by correcting for informative censoring with inverse
probability censoring weighting (IPCW). To this end, we revised UNOS-MELD
on patients with cirrhosis who were on the Eurotransplant waiting list
between 2007 and 2019 (n=13,274) with Cox models with as endpoints
90-day survival (a) from registration and (b) from weekly drawn
calendar-time cross-sections. We refer to the score revised from
cross-section with IPCW as <em>DynReMELD</em>. We compare DynReMELD to
UNOS-MELD and ReMELD, a prior revision of UNOS-MELD for Eurotransplant,
in a geographical validation.</p>
<p>Our results show that revising MELD from calendar-time cross-sections leads to significantly
different MELD coefficients. IPCW increases estimates of absolute 90-day
waiting list mortality risks by approximately 10 percentage points.
DynReMELD shows improved discrimination compared to UNOS-MELD (delta c-index:
0.0040, p&lt;0.001) and ReMELD (delta c-index: 0.0015, p&lt;0.01), with
differences comparable in magnitude to the addition of an extra
biomarker to MELD (delta c-index: ±0.0030).</p>
<p>Correction for selection bias by transplantation or delisting with inverse
probability censoring weighting does not
improve the discrimination of revised MELD scores, but does substantially
increase estimates of absolute 90-day mortality risks. Revision from
cross-section uses waiting list data more efficiently, and improves
discrimination compared to revision of MELD exclusively based on
the information available at listing.</p>
<p></p>
<div id="introduction" class="section level2 hasAnchor" number="3.1">
<h2><span class="header-section-number">3.1</span> Introduction<a href="CHdynremeld.html#introduction" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>Eurotransplant calculates MELD scores with a formula originally introduced by
UNOS in 2002. We refer to this score as UNOS-MELD. Various limitations of UNOS-MELD
have been described, including that</p>
<ol style="list-style-type: decimal">
<li><p>it was not developed to predict mortality on the liver waiting list <span class="citation"><a href="#ref-malinchocModelPredictPoor2000">[33]</a></span>,</p></li>
<li><p>it overemphasizes renal dysfunction
<span class="citation"><a href="#ref-sharmaReweightingModelEndStage2008">[40]</a></span>,</p></li>
<li><p>it uses biomarker caps that are not evidence-based
<span class="citation"><a href="#ref-leiseRevisedModelEndstage2011">[41]</a></span>,</p></li>
<li><p>it is poorly calibrated for specific subgroups, such as
patients with hyponatremia <span class="citation"><a href="#ref-kimHyponatremiaMortalityPatients2008a">[37]</a></span>.</p></li>
</ol>
<p>These limitations have motivated several studies to revise MELD, either
by re-estimating the equation’s coefficients using registry data on
liver transplant candidates (e.g., <span class="citation"><a href="#ref-sharmaReweightingModelEndStage2008">[40]</a>, <a href="#ref-leiseRevisedModelEndstage2011">[41]</a></span>), or by expanding the scoring system
with new biomarkers (e.g., MELD-Na
<span class="citation"><a href="#ref-kimHyponatremiaMortalityPatients2008a">[37]</a></span> or MELD 3.0
<span class="citation"><a href="#ref-kimMELD3point0">[20]</a></span>). In 2020, the equation’s coefficients and caps of MELD
were revised by Goudsmit et al. using retrospective data from Eurotransplant.
The resulting score is referred to as the “ReMELD” score <span class="citation"><a href="#ref-goudsmitRefittingModelEndstage2020">[42]</a></span>.</p>
<p>MELD revision typically proceeds by modeling waiting list mortality up to
90 days after waiting list registration based on biomarkers reported at
registration (e.g., <span class="citation"><a href="#ref-kimMELD3point0">[20]</a>, <a href="#ref-kimHyponatremiaMortalityPatients2008a">[37]</a>, <a href="#ref-leiseRevisedModelEndstage2011">[41]</a>, <a href="#ref-goudsmitRefittingModelEndstage2020">[42]</a></span>). This <em>“from registration”</em> approach
poorly aligns with the clinical use of MELD: in allocation, candidates are prioritized
on their last reported MELD score, and not on the MELD score that was reported at listing. Moreover, revising MELD <em>“from registration”</em> ignores
waiting list deaths that occur more than 90 days after listing, which are
two-thirds of all liver waiting list deaths within Eurotransplant.</p>
<p>Previously, such waste of statistical information was avoided by
adjusting for MELD biomarkers as time-varying covariates
(<span class="citation"><a href="#ref-merionLongitudinalAssessmentMortality2003">[39]</a>, <a href="#ref-sharmaReweightingModelEndStage2008">[40]</a></span>).
However, MELD biomarkers also increase as part of the death process
<span class="citation"><a href="#ref-bambhaPredictingSurvivalPatients2004">[56]</a></span>, such that use of
MELD biomarkers as time-varying covariates leads to issues of reverse
causality. This reverse causality problem is exacerbated by the fact that MELD scores can be updated voluntarily at any time and by the fact that sicker patients are required
to update their MELD scores more frequently.</p>
<p>To prevent these issues, we propose revising MELD <em>“from cross-section”</em>
using methodology developed by Gong and Schaubel
<span class="citation"><a href="#ref-gongPartlyConditionalEstimation2013">[57]</a></span>. With this approach MELD is
revised by modeling the remaining time-until-death from pre-specified
calendar-time cross-sections rather than from registration. Biomarkers
measured after listing and deaths recorded more than 90
days after listing thereby inform MELD revision. To prevent issues of reverse
causality, adjustment at each cross-section is for historical biomarker
information only. The evolution of biomarkers after the cross-section
date affects survival, transplantation and delisting rates, which makes
transplantation and delisting informative censoring mechanisms. Prior revisions
of MELD censor patients at transplantation or delisting, which introduces
bias. We study how MELD revision is
affected by correcting for dependent censoring with inverse
probability censoring weighting, which was first proposed by Gong and Schaubel <span class="citation"><a href="#ref-gongPartlyConditionalEstimation2013">[57]</a></span>.</p>
</div>
<div id="materials-and-methods" class="section level2 hasAnchor" number="3.2">
<h2><span class="header-section-number">3.2</span> Materials and methods<a href="CHdynremeld.html#materials-and-methods" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<div id="study-population-and-data" class="section level3 hasAnchor" number="3.2.1">
<h3><span class="header-section-number">3.2.1</span> Study population and data<a href="CHdynremeld.html#study-population-and-data" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Adult patients with any active waiting list status on the Eurotransplant
waiting list between December 16, 2006, and December 31, 2019, were extracted from
the Eurotransplant database. Only patients with cirrhosis were included
in the study, which is the patient group on which UNOS-MELD was originally
validated. Patients with other diagnoses, those prioritized through exception
points, and those awaiting a repeat transplantation or combined transplantation
were excluded (except combined liver-kidney transplantation
candidates). Patients with impossible values for MELD biomarkers (e.g., all
zeroes for bilirubin, creatinine, and the INR) were excluded.</p>
<p>To activate a candidate on the liver waiting list, centers have to report MELD
biomarkers to Eurotransplant. Reported MELD scores are valid for a maximum of one
year, and expire in a shorter time window for sicker patients (within seven days for MELD scores greater than 25
<span class="citation"><a href="#ref-ETLiverMan2025">[58]</a></span>). Failure to update the MELD score results in the
lowest possible MELD score of 6 being used for allocation. Consequently,
MELD updates are available for most transplant candidates in the Eurotransplant
database. Centers can set
candidates to non-transplantable (NT) if they are temporarily not available
for transplantation, which ensures that the transplant center is not
contacted with offers for these patients.</p>
</div>
<div id="meld-scores-unos-meld-and-remeld" class="section level3 hasAnchor" number="3.2.2">
<h3><span class="header-section-number">3.2.2</span> MELD scores, UNOS-MELD and ReMELD<a href="CHdynremeld.html#meld-scores-unos-meld-and-remeld" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>We define a MELD scoring system as a system that calculates a score based
on serum bilirubin, serum creatinine and the INR, using the following formula:</p>
<p><span class="math display">\[\text{intercept}\  + \text{coef}_{\text{bili}}\ln\left( \text{bili} \right) + \ \text{coef}_{\text{crea}}\ln\left( \text{crea} \right) +
\text{coef}_{\text{INR}}\ln\left( \text{INR} \right),\]</span></p>
<p>with serum bilirubin and serum creatinine measured in mg/dl. A specific MELD
score proposes values for the intercept and coefficients, and bounds for the
values of MELD biomarkers. A MELD score also has to propose how to calculate
MELD scores for candidates who received dialysis twice in the week before
measurement of MELD biomarkers (henceforth “patients on biweekly dialysis”),
since dialysis reduces measured creatinine levels. Eurotransplant currently uses UNOS-MELD for allocation, i.e.</p>
<p><span class="math display">\[6.43\  + 3.78\ln\left( \text{bilirubin} \right) + 9.57\ln\left( \text{creatinine} \right) + 11.20\ln\left( \text{INR} \right),\]</span></p>
<p>in which creatinine is capped at 4.0 mg/dl, a lower limit of 1.0 is imposed on
all biomarkers, and creatinine is set to 4.0 mg/dl for patients on biweekly
dialysis.</p>
<p>Various revisions of MELD have been proposed (e.g., see
<span class="citation"><a href="#ref-leiseRevisedModelEndstage2011">[41]</a>, <a href="#ref-goudsmitRefittingModelEndstage2020">[42]</a>, <a href="#ref-bambhaPredictingSurvivalPatients2004">[56]</a></span>).
One alternative – that was
developed specifically for Eurotransplant – is ReMELD
<span class="citation"><a href="#ref-goudsmitRefittingModelEndstage2020">[42]</a></span>, which calculates the score as</p>
<p><span class="math display">\[8.422\  + 7.728\ln\left( \text{bili} \right) + \ 3.446\ \ln\left( \text{crea} \right) + 10.597\ln\left( \text{INR} \right).\]</span></p>
<p>In calculating ReMELD scores, bilirubin is bounded between 0.3 and 27 mg/dl, the INR is
bounded between 0.1 and 2.6, and creatinine is bounded between 0.7 and 2.5 mg/dl. Creatinine is
also set to the upper cap of 2.5 mg/dl for patients on biweekly dialysis.</p>
</div>
<div id="revision-from-registration-vs.-revision-from-cross-section" class="section level3 hasAnchor" number="3.2.3">
<h3><span class="header-section-number">3.2.3</span> Revision <em>“from registration” vs. “revision from cross-section”</em><a href="CHdynremeld.html#revision-from-registration-vs.-revision-from-cross-section" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>In revising MELD, authors typically re-estimate MELD coefficients <em>“from
registration”</em>. By this, we mean that authors use Cox proportional hazards models
to model 90-day waiting list mortality after registration with adjustment
for MELD biomarkers that were reported at listing. Coefficients for the MELD scoring system are then commonly derived by rescaling the estimated regression coefficients (<span class="math inline">\(\widehat{\beta}\)</span>) to the UNOS-MELD scale. This rescaling is typically achieved by matching quantiles of the linear predictor to corresponding quantiles of UNOS-MELD scores (e.g., <span class="citation"><a href="#ref-leiseRevisedModelEndstage2011">[41]</a>, <a href="#ref-goudsmitRefittingModelEndstage2020">[42]</a></span>).
This <em>“from registration”</em> approach ignores any MELD measurements recorded after registration, as
well as patient deaths recorded more than 90 days after registration. We
propose to avoid such waste of statistical information by revising
MELD with a <em>“from cross-section”</em> approach. The key differences between these
approaches are illustrated in Figure <a href="CHdynremeld.html#fig:ch3fig1">3.1</a>.</p>
<p>The <em>“from cross-section”</em> approach uses methodology developed by Gong and Schaubel
<span class="citation"><a href="#ref-gongPartlyConditionalEstimation2013">[57]</a></span>, and models the remaining
time-until-death from pre-specified calendar-time cross-sections (see
right panel, Figure <a href="CHdynremeld.html#fig:ch3fig1">3.1</a>). This approach uses cross-section calendar
times as the time origin, and the time elapsed since the cross-section date as
the timescale. The coefficients are estimated with a Cox proportional hazards model
that is stratified by the cross-section. At each cross-section only
patients with an active registration (i.e., without non-transplantable
status) are included in the analysis, and Cox models adjust only for
biomarker information reported <em>before</em> the cross-section. We point out
that patients waiting at multiple calendar-time cross-sections
contribute multiple observations to the Cox model fit (right panel,
Figure <a href="CHdynremeld.html#fig:ch3fig1">3.1</a>). Thereby, revision of MELD is also affected by (i)
waiting list deaths that occur more than 90 days after listing, and (ii)
biomarker measurements taken after listing.</p>
<p></p>
<div class="figure" style="text-align: center"><span style="display:block;" id="fig:ch3fig1"></span>
<img src="figures/ch3/figure1.png" alt="Illustration of from “registration” and “from cross-section” approaches to modeling waiting list mortality. For revision of MELD, typically 90-day time-stopped Cox models are used. The “from registration” approach (left) uses time since registration as the timescale and adjusts for biomarkers reported at registration. The “from cross-section” approach (right) models time-until-death from cross-section dates, pre-specified in calendar time, and adjusts for MELD biomarkers reported before the cross-section date. WL, waiting list." width="87%" />
<p class="caption">
Figure 3.1: Illustration of from “registration” and “from cross-section” approaches to modeling waiting list mortality. For revision of MELD, typically 90-day time-stopped Cox models are used. The “from registration” approach (left) uses time since registration as the timescale and adjusts for biomarkers reported at registration. The “from cross-section” approach (right) models time-until-death from cross-section dates, pre-specified in calendar time, and adjusts for MELD biomarkers reported before the cross-section date. WL, waiting list.
</p>
</div>
<p>
</p>
<p>In this chapter, we compare revision of MELD <em>“from
registration”</em> to revision <em>“from cross-section”</em>. In revising MELD
<em>“from registration”</em>, we stratify models by country of listing. For the
<em>“from cross-section”</em> approach, we use weekly cross-sections from
December 22, 2006 to December 31, 2019 and stratify Cox models by the
candidate’s country of listing and
by cross-section. The candidate survival status 90 days after the cross-section date is
used as an endpoint, and adjustment at each cross-section is for the
last reported MELD biomarker values before the cross-section date.</p>
</div>
<div id="outcome-definition" class="section level3 hasAnchor" number="3.2.4">
<h3><span class="header-section-number">3.2.4</span> Outcome definition<a href="CHdynremeld.html#outcome-definition" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Time-until-death is modeled with 90-day time-stopped Cox PH
models. Delisted patients who die within 90 days of deregistration are
treated as if they had died on waiting list exit (as in
<span class="citation"><a href="#ref-goudsmitRefittingModelEndstage2020">[42]</a></span>). Patients who were
transplanted or delisted within 90 days are censored.
Inverse probability censoring weighting (IPCW) is used to correct for
selection bias due to transplantation and delisting.</p>
</div>
<div id="inverse-probability-censoring-weighting-to-correct-for-dependent-censoring" class="section level3 hasAnchor" number="3.2.5">
<h3><span class="header-section-number">3.2.5</span> Inverse probability censoring weighting to correct for dependent censoring<a href="CHdynremeld.html#inverse-probability-censoring-weighting-to-correct-for-dependent-censoring" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Consistent estimation of parameters <span class="math inline">\(\beta\)</span> with a standard Cox PH model
requires that the censoring process is independent of survival,
conditional on covariates. This independent censoring
assumption is violated for both the <em>“from registration”</em> and <em>“from
cross-section”</em> approaches, because only MELD biomarkers
reported at listing (or before the cross-section date) are included as covariates, while MELD biomarkers
reported after listing (or cross-section) affect patient survival and transplantation/delisting rates.
Gong and Schaubel proposed a procedure
that can correct for the bias introduced by dependent censoring due to transplantation.
This procedure weighs candidates by their inverse probability of having been transplanted
between the cross-section and exit date (IPCW-T weights, T for transplantation).
Such probabilities can be estimated using an extended Cox proportional hazards model, which
uses the candidate’s transplantation status as the outcome.</p>
<p>We expand in this chapter on Gong and Schaubel’s approach by also
constructing inverse probability censoring weights for delisting
(IPCW delisting (IPCW-D) weights). Under the assumption that delisting
and transplantation are conditionally independent, a joint inverse
probability censoring weight can then be obtained by multiplying
IPCW-T and IPCW-D weights (see also <span class="citation"><a href="#ref-schnellingerMitigatingSelectionBias2021">[59]</a></span>). Details on how weights
were constructed are included in Appendix <a href="APPipcw.html#APPipcw">A</a>. In this chapter, we assess
how IPCW affects revised MELD coefficients both <em>“from registration”</em>
and <em>“from cross-section”</em>.</p>
<p></p>
</div>
<div id="adjustment-variables-caps-and-functional-forms" class="section level3 hasAnchor" number="3.2.6">
<h3><span class="header-section-number">3.2.6</span> Adjustment variables, caps, and functional forms<a href="CHdynremeld.html#adjustment-variables-caps-and-functional-forms" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Cox PH models adjust for variables present in MELD, i.e., serum bilirubin,
serum creatinine, and the INR. Spline terms are used to assess
whether the relation between log-transformed biomarkers and the
mortality rate is approximately linear. Final models use
logarithmic transformations for the biomarkers, with lower and upper
limits for biomarkers optimized over regions where violation of
log-linearity was visually apparent (as in
Leise et al. <span class="citation"><a href="#ref-leiseRevisedModelEndstage2011">[41]</a></span> and Goudsmit et al. 
<span class="citation"><a href="#ref-goudsmitRefittingModelEndstage2020">[42]</a></span>).</p>
<p>On the Eurotransplant liver waiting list, more than 10% of patients receive biweekly dialysis, and
measured creatinine is not used to calculate lab-MELD scores for these patients.
To also ignore measured creatinine in revising MELD for these patients, we set
creatinine to 1.0 mg/dl for patients on dialysis (leading to <span class="math inline">\(\ln(1.0) = 0\)</span> MELD points).
Instead, we use whether the patient receives biweekly dialysis as an adjustment variable.</p>
</div>
<div id="development-and-validation-cohorts" class="section level3 hasAnchor" number="3.2.7">
<h3><span class="header-section-number">3.2.7</span> Development and validation cohorts<a href="CHdynremeld.html#development-and-validation-cohorts" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>To enable revision and geographical validation for all Eurotransplant countries,
we aimed to use a 70%/30% center-based split per country. Such a
split was feasible for Germany (70%/30%), Belgium (70.1%/29.9%)
Austria (62.6%/37.4%), and the Netherlands (74.3%/25.7%), but not for
Hungary (1 center), Slovenia (1 center), and Croatia (1 large center, 2
very small centers). Therefore, Hungarian, Slovenian and Croatian
patients (11% of the total cohort) were randomly split into 70%/30%
development/validation cohorts.</p>
<p>All models – including those used to estimate inverse probability
weights – were fitted on the development cohort only. The validation
cohort was used to compare the newly developed score – which we name <em>DynReMELD</em> – to
ReMELD and UNOS-MELD.</p>
</div>
<div id="comparison-to-unos-meld-and-remeld" class="section level3 hasAnchor" number="3.2.8">
<h3><span class="header-section-number">3.2.8</span> Comparison to UNOS-MELD and ReMELD<a href="CHdynremeld.html#comparison-to-unos-meld-and-remeld" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>We revised MELD <em>“from registration”</em> and <em>“from cross-section”</em> both
with and without IPCW. Without IPCW, MELD was also revised with ReMELD’s
linear predictor used as an offset. This enables assessment of whether
revision of MELD on all cirrhotic patients yields a significantly
different equation from ReMELD. We define <em>DynReMELD</em> as the equation
obtained by quantile matching the linear predictor revised <em>“from
cross-section”</em> with IPCW to quantiles of UNOS-MELD.
We compare the discrimination of MELD, ReMELD and DynReMELD using the c-index
in the validation cohort. This c-index quantifies the degree to which patients with a
higher score die earlier on the Eurotransplant waiting list. In the literature,
the c-index is most commonly estimated with Harrell’s c-index, which is a
consistent estimator of the c-index in case of independent censoring. Because
this assumption is implausible in liver transplantation, we use Gerd’s c-index <span class="citation"><a href="#ref-gerdsEstimatingTimedependentConcordance2012">[60]</a></span>.
This c-index is a consistent estimator for the c-index provided that a consistent
estimator of the conditional probability of remaining uncensored is available
<span class="citation"><a href="#ref-gerdsEstimatingTimedependentConcordance2012">[60]</a>, <a href="#ref-Hartman2025">[61]</a></span>.
We estimate Gerd’s c-indices for two separate prediction tasks,
namely (i) prediction of time-until-death from listing based on biomarkers
reported at listing,
and (ii) prediction of remaining time-until-death from calendar-time
cross-sections based on the last reported MELD biomarkers.</p>
<p>Assessment of calibration for <em>DynReMELD</em> is complicated by the fact
that models developed with IPCW are counterfactual prediction models,
and it is not clear how to assess calibration for such models
<span class="citation"><a href="#ref-linScopingReviewCausal2021">[62]</a></span>. Instead of assessing calibration, we report estimates
of absolute 90-day survival risks for <em>DynReMELD</em> estimated with and
without IPCW. These 90-day survival estimates are of interest to Eurotransplant,
as Eurotransplant uses them to convert awarded exception scores to the MELD scale.</p>
</div>
</div>
<div id="results" class="section level2 hasAnchor" number="3.3">
<h2><span class="header-section-number">3.3</span> Results<a href="CHdynremeld.html#results" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>This study included 13,343 liver waiting list registrations for 13,274
patients<a href="#fn1" class="footnote-ref" id="fnref1"><sup>1</sup></a> with cirrhosis waiting for a first
liver transplant. We note that candidates with exception points (for example,
HCC) were not included in our study cohort. We excluded 107 patients (&lt;1%)
because they reported impossible MELD biomarker values (e.g., zeroes for all
biomarkers). Baseline characteristics of development and validation cohorts
are included in Table <a href="CHdynremeld.html#tab:ch3tab1baseline">3.1</a>.</p>
<table class="table" style="font-size: 15px; margin-left: auto; margin-right: auto;">
<caption style="font-size: initial !important;">
<span id="tab:ch3tab1baseline">Table 3.1: </span>Baseline characteristics and observed waiting list outcomes for the development and validation cohorts.
</caption>
<thead>
<tr>
<th style="text-align:left;">
variable
</th>
<th style="text-align:left;">
level
</th>
<th style="text-align:center;">
development (n=9,288)
</th>
<th style="text-align:center;">
validation (n=4,055)
</th>
<th style="text-align:left;">
p-value
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
UNOS-MELD<br>at listing
</td>
<td style="text-align:left;">
mean (Q1-Q3)
</td>
<td style="text-align:center;">
21.0 (13.0-28.0)
</td>
<td style="text-align:center;">
20.3 (12.0-28.0)
</td>
<td style="text-align:left;">
&lt;0.001
</td>
</tr>
<tr>
<td style="text-align:left;">
bilirubin (mg/dl)<br>at listing
</td>
<td style="text-align:left;">
mean (Q1-Q3)
</td>
<td style="text-align:center;">
7.53 (1.63-8.54)
</td>
<td style="text-align:center;">
7.06 (1.43-8.00)
</td>
<td style="text-align:left;">
0.009
</td>
</tr>
<tr>
<td style="text-align:left;">
creatinine (mg/dl)<br>at listing
</td>
<td style="text-align:left;">
mean (Q1-Q3)
</td>
<td style="text-align:center;">
1.54 (0.810-1.75)
</td>
<td style="text-align:center;">
1.46 (0.803-1.60)
</td>
<td style="text-align:left;">
0.001
</td>
</tr>
<tr>
<td style="text-align:left;">
INR
</td>
<td style="text-align:left;">
mean (Q1-Q3)
</td>
<td style="text-align:center;">
1.79 (1.29-2.00)
</td>
<td style="text-align:center;">
1.75 (1.21-1.91)
</td>
<td style="text-align:left;">
0.024
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="2">
biweekly dialysis
</td>
<td style="text-align:left;">
yes
</td>
<td style="text-align:center;">
1096 (11.8%)
</td>
<td style="text-align:center;">
504 (12.4%)
</td>
<td style="text-align:left;">
0.318
</td>
</tr>
<tr>
<td style="text-align:left;">
no
</td>
<td style="text-align:center;">
8192 (88.2%)
</td>
<td style="text-align:center;">
3551 (87.6%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="2">
patient sex
</td>
<td style="text-align:left;">
male
</td>
<td style="text-align:center;">
6226 (67.0%)
</td>
<td style="text-align:center;">
2761 (68.1%)
</td>
<td style="text-align:left;">
0.239
</td>
</tr>
<tr>
<td style="text-align:left;">
female
</td>
<td style="text-align:center;">
3062 (33.0%)
</td>
<td style="text-align:center;">
1294 (31.9%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
age<br>at listing
</td>
<td style="text-align:left;">
mean (Q1-Q3)
</td>
<td style="text-align:center;">
53.8 (49.0-61.0)
</td>
<td style="text-align:center;">
54.4 (49.0-61.0)
</td>
<td style="text-align:left;">
&lt;0.001
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="5">
cirrhosis aetiology
</td>
<td style="text-align:left;">
alcoholic
</td>
<td style="text-align:center;">
4949 (53.3%)
</td>
<td style="text-align:center;">
2292 (56.5%)
</td>
<td style="text-align:left;">
&lt;0.001
</td>
</tr>
<tr>
<td style="text-align:left;">
autoimmune/cryptogenic
</td>
<td style="text-align:center;">
1596 (17.2%)
</td>
<td style="text-align:center;">
619 (15.3%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
hepatitic
</td>
<td style="text-align:center;">
1712 (18.4%)
</td>
<td style="text-align:center;">
528 (13.0%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
metabolic/other
</td>
<td style="text-align:center;">
669 (7.2%)
</td>
<td style="text-align:center;">
484 (11.9%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
NAFLD
</td>
<td style="text-align:center;">
362 (3.9%)
</td>
<td style="text-align:center;">
132 (3.3%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="5">
outcome by<br>Dec 31, 2019
</td>
<td style="text-align:left;">
waiting list death
</td>
<td style="text-align:center;">
2265 (24.4%)
</td>
<td style="text-align:center;">
980 (24.2%)
</td>
<td style="text-align:left;">
&lt;0.001
</td>
</tr>
<tr>
<td style="text-align:left;">
transplanted
</td>
<td style="text-align:center;">
5068 (54.6%)
</td>
<td style="text-align:center;">
2105 (51.9%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
removed (other)
</td>
<td style="text-align:center;">
700 (7.5%)
</td>
<td style="text-align:center;">
278 (6.9%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
recovered
</td>
<td style="text-align:center;">
610 (6.6%)
</td>
<td style="text-align:center;">
327 (8.1%)
</td>
<td style="text-align:left;">
</td>
</tr>
<tr>
<td style="text-align:left;">
waiting
</td>
<td style="text-align:center;">
645 (6.9%)
</td>
<td style="text-align:center;">
365 (9.0%)
</td>
<td style="text-align:left;">
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup></sup> NAFLD; non-alcoholic fatty liver disease.
</td>
</tr>
</tfoot>
</table>
<p></p>
<div id="number-of-meld-scores-informing-the-revision-of-meld" class="section level3 hasAnchor" number="3.3.1">
<h3><span class="header-section-number">3.3.1</span> Number of MELD scores informing the revision of MELD<a href="CHdynremeld.html#number-of-meld-scores-informing-the-revision-of-meld" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>With cross-sections, 8,779 out of 9,288 (95%) patients in the
development cohort are active at a cross-section date, and inform
revision of MELD. The remaining 509 patients
were transplanted, delisted, or marked non-transplantable before a cross-section date
was reached (which means they exited the waiting list within at most 7 days of listing). We note that these 509 candidates do not inform revision of
MELD from cross-section.</p>
<p>Biomarker measurements taken after listing are ignored by the <em>“from registration”</em> approach,
while these measurements inform revision of MELD with a <em>“from cross-section”</em> approach.
Table <a href="CHdynremeld.html#tab:ch3tab1">3.2</a> shows that the number of unique MELD scores
informing MELD revision increases about sevenfold with a <em>“from
cross-section”</em> approach, from 9,264 to 67,433.
The number of observed waiting list deaths and event rates also increase
substantially with the <em>“from cross-section”</em> approach. For example, <em>“from
cross-section”</em> the number of included MELD scores between 36 and 40
triples from 456 to 1,248, with 47% of these patients dying 90 days
after cross-section, compared to only 31% <em>“from registration”</em>.</p>
<p>
</p>
<table class="table" style="font-size: 14px; margin-left: auto; margin-right: auto;">
<caption style="font-size: initial !important;">
<span id="tab:ch3tab1">Table 3.2: </span>Number of UNOS-MELD scores used for the model fit in the “from registration” approach, and “from cross-section” approach.
</caption>
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="3">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
outcome within 90 days
</div>
</th>
</tr>
<tr>
<th style="text-align:left;">
group
</th>
<th style="text-align:center;">
dataset
</th>
<th style="text-align:center;">
# usable MELD scores
</th>
<th style="text-align:center;">
death or removed unfit
</th>
<th style="text-align:center;">
transplanted
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;vertical-align: middle !important;" rowspan="2">
</td>
<td style="text-align:center;padding-left:0.5em !important;">
from registration
</td>
<td style="text-align:center;">
9264
</td>
<td style="text-align:center;">
846 (9.1%)
</td>
<td style="text-align:center;">
2598 (28.0%)
</td>
</tr>
<tr>
<td style="text-align:center;">
from cross-section
</td>
<td style="text-align:center;padding-left:0.5em !important;">
67433
</td>
<td style="text-align:center;">
5906 (8.8%)
</td>
<td style="text-align:center;">
11071 (16.4%)
</td>
</tr>
<tr grouplength="8">
<td colspan="5" style="border-bottom: 1px solid;">
<strong>by MELD</strong>
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;padding-left: 2em;" rowspan="2" indentlevel="1">
6-14
</td>
<td style="text-align:center;padding-left:0.5em !important;">
from registration
</td>
<td style="text-align:center;">
3291
</td>
<td style="text-align:center;">
67 (2.0%)
</td>
<td style="text-align:center;">
389 (11.8%)
</td>
</tr>
<tr>
<td style="text-align:center;padding-left: 2em;" indentlevel="1">
from cross-section
</td>
<td style="text-align:center;padding-left:0.5em !important;">
28192
</td>
<td style="text-align:center;">
454 (1.6%)
</td>
<td style="text-align:center;">
1565 (5.6%)
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;padding-left: 2em;" rowspan="2" indentlevel="1">
15-24
</td>
<td style="text-align:center;padding-left:0.5em !important;">
from registration
</td>
<td style="text-align:center;">
4355
</td>
<td style="text-align:center;">
382 (8.8%)
</td>
<td style="text-align:center;">
1199 (27.5%)
</td>
</tr>
<tr>
<td style="text-align:center;padding-left: 2em;" indentlevel="1">
from cross-section
</td>
<td style="text-align:center;padding-left:0.5em !important;">
30806
</td>
<td style="text-align:center;">
2938 (9.5%)
</td>
<td style="text-align:center;">
5766 (18.7%)
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;padding-left: 2em;" rowspan="2" indentlevel="1">
25-35
</td>
<td style="text-align:center;padding-left:0.5em !important;">
from registration
</td>
<td style="text-align:center;">
1160
</td>
<td style="text-align:center;">
253 (21.8%)
</td>
<td style="text-align:center;">
711 (61.3%)
</td>
</tr>
<tr>
<td style="text-align:center;padding-left: 2em;" indentlevel="1">
from cross-section
</td>
<td style="text-align:center;padding-left:0.5em !important;">
7187
</td>
<td style="text-align:center;">
1922 (26.7%)
</td>
<td style="text-align:center;">
3144 (43.7%)
</td>
</tr>
<tr>
<td style="text-align:left;vertical-align: middle !important;padding-left: 2em;" rowspan="2" indentlevel="1">
36-40
</td>
<td style="text-align:center;padding-left:0.5em !important;">
from registration
</td>
<td style="text-align:center;">
458
</td>
<td style="text-align:center;">
144 (31.4%)
</td>
<td style="text-align:center;">
299 (65.3%)
</td>
</tr>
<tr>
<td style="text-align:center;padding-left: 2em;" indentlevel="1">
from cross-section
</td>
<td style="text-align:center;padding-left:0.5em !important;">
1248
</td>
<td style="text-align:center;">
592 (47.4%)
</td>
<td style="text-align:center;">
596 (47.8%)
</td>
</tr>
</tbody>
</table>
<p>
</p>
</div>
<div id="revising-the-meld-formula-using-cox-models" class="section level3 hasAnchor" number="3.3.2">
<h3><span class="header-section-number">3.3.2</span> Revising the MELD formula using Cox models<a href="CHdynremeld.html#revising-the-meld-formula-using-cox-models" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Evidence-based caps were derived using the procedure proposed by Leise et al.
<span class="citation"><a href="#ref-leiseRevisedModelEndstage2011">[41]</a></span>. This procedure involves estimating
Cox proportional hazard models with different caps applied and
choosing the caps that result in the maximal log-likelihood. The procedure
is applied separately for each biomarker, with the biomarker under consideration
modeled linearly and the other biomarkers modeled non-linearly using
spline terms. Figure <a href="CHdynremeld.html#fig:ch3sfig3">3.2</a> summarizes the results
of this procedure. The optimal caps were found to be 0.6–55 mg/dl for bilirubin,
0.8–2.5 mg/dl for serum
creatinine, and 1.0–3.0 for the INR.</p>
<div class="figure" style="text-align: center"><span style="display:block;" id="fig:ch3sfig3"></span>
<img src="figures/ch3/fig_ll.png" alt="Heatmaps of the log-likelihood values for combinations of lower and upper bounds for serum bilirubin (mg/dl), serum creatinine (mg/dl), and the INR. Blue dots represent the optimal caps in the development data; purple dots represent the caps derived for ReMELD." width="100%" />
<p class="caption">
Figure 3.2: Heatmaps of the log-likelihood values for combinations of lower and upper bounds for serum bilirubin (mg/dl), serum creatinine (mg/dl), and the INR. Blue dots represent the optimal caps in the development data; purple dots represent the caps derived for ReMELD.
</p>
</div>
<p></p>
<div id="coefficients-revised-from-registration" class="section level4 hasAnchor" number="3.3.2.1">
<h4><span class="header-section-number">3.3.2.1</span> Coefficients revised from registration<a href="CHdynremeld.html#coefficients-revised-from-registration" class="anchor-section" aria-label="Anchor link to header"></a></h4>
<p>Panel A of Table <a href="CHdynremeld.html#tab:ch3tab2">3.3</a> shows MELD coefficients revised <em>“from
registration”</em>. The first column shows that parameter estimates are
jointly not significantly different from 0
(<span class="math inline">\(\chi_{3}^{2}\)</span> = 4.1,p = 0.25) when using ReMELD’s prognostic
index as an offset. The insignificance of these estimates confirms
that ReMELD adequately predicts 90-day mortality <em>“from registration”</em> for all cirrhotic
patients. IPCW changes the biomarker
coefficients only slightly (by less than a standard error).</p>
</div>
<div id="coefficients-revised-from-cross-section" class="section level4 hasAnchor" number="3.3.2.2">
<h4><span class="header-section-number">3.3.2.2</span> Coefficients revised from cross-section<a href="CHdynremeld.html#coefficients-revised-from-cross-section" class="anchor-section" aria-label="Anchor link to header"></a></h4>
<p>Panel B of Table <a href="CHdynremeld.html#tab:ch3tab2">3.3</a> shows MELD coefficients revised <em>“from
cross-section”</em>. The first column shows that coefficients are jointly
significantly different from 0 with ReMELD used as an offset
(<span class="math inline">\(\chi_{3}^{2}\)</span> = 801,p &lt; 0.001). Hence, ReMELD does not adequately
predict 90-day mortality from cross-section. Estimated coefficients
suggest ReMELD underestimates the effect of creatinine
(<span class="math inline">\(z\)</span>= 5.2, p &lt; 0.001) and bilirubin (<span class="math inline">\(z\)</span> = 6.1, p &lt; 0.001), but not
the INR (<span class="math inline">\(z = 0.3,p = 0.76\)</span>). IPCW appears to increase MELD
biomarker coefficients slightly (by less than a standard deviation).</p>
<p>Table <a href="CHdynremeld.html#tab:ch3tab2relweights">3.4</a> shows the relative weights put on the MELD
components by the equation revised from cross-section with IPCW.
These weights, originally defined by Sharma et al. <span class="citation"><a href="#ref-sharmaReweightingModelEndStage2008">[40]</a></span>,
quantify the increase in MELD score resulting from a one-standard deviation increase
in a given biomarker, relative to a one-standard deviation increase in all biomarkers.
These weights also show that the refitted equation puts more weight on bilirubin (41%)
than UNOS-MELD (36%) and ReMELD (37%), and puts less weight on the INR
(28% vs. 32% for UNOS-MELD and 34% for ReMELD).</p>
<p>
</p>
<table class="table" style="margin-left: auto; margin-right: auto;">
<caption>
<span id="tab:ch3tab2">Table 3.3: </span>Comparison of MELD coefficients for different model fits from registration (panel A) and “from cross-section” (panel B), for (1) revision with ReMELD’s prognostic index as an offset, (2) revision without the offset, and (3) revision with IPCW.
</caption>
<thead>
<tr>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: left; " colspan="4">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
panel A - from registration
</div>
</th>
</tr>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:center;">
<ol style="list-style-type: decimal">
<li>ReMELD offset
</th>
<th style="text-align:center;">
<ol start="2" style="list-style-type: decimal">
<li>refitted, no IPCW
</th>
<th style="text-align:center;">
<ol start="3" style="list-style-type: decimal">
<li>refitted, IPCW
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
ln(bilirubin (mg/dL))
</td>
<td style="text-align:center;">
0.03 (0.05)
</td>
<td style="text-align:center;">
0.69 (0.05)
</td>
<td style="text-align:center;">
0.73 (0.06)
</td>
</tr>
<tr>
<td style="text-align:left;">
ln(creatinine<span class="math inline">\(^1\)</span> (mg/dL))
</td>
<td style="text-align:center;">
0.10 (0.09)
</td>
<td style="text-align:center;">
1.62 (0.01)
</td>
<td style="text-align:center;">
1.61 (0.12)
</td>
</tr>
<tr>
<td style="text-align:left;">
ln(INR)
</td>
<td style="text-align:center;">
0.12 (0.17)
</td>
<td style="text-align:center;">
2.02 (0.17)
</td>
<td style="text-align:center;">
2.19 (0.21)
</td>
</tr>
<tr>
<td style="text-align:left;">
biweekly dialysis
</td>
<td style="text-align:center;">
</td>
<td style="text-align:center;">
1.85 (0.12)
</td>
<td style="text-align:center;">
1.73 (0.13)
</td>
</tr>
<tr>
<td style="text-align:left;">
LR Test
</td>
<td style="text-align:center;">
4.1 (df = 3)
</td>
<td style="text-align:center;">
1482 (df = 4)
</td>
<td style="text-align:center;">
1883 (df = 4)
</td>
</tr>
</tbody>
</table>
<table class="table" style="margin-left: auto; margin-right: auto;">
<caption>
<span id="tab:ch3tab2">Table 3.3: </span>
</caption>
<thead>
<tr>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: left; " colspan="4">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
panel B - from cross-section
</div>
</th>
</tr>
<tr>
<th style="text-align:left;">
</th>
<th style="text-align:center;">
<ol style="list-style-type: decimal">
<li>ReMELD offset
</th>
<th style="text-align:center;">
<ol start="2" style="list-style-type: decimal">
<li>refitted, no IPCW
</th>
<th style="text-align:center;">
<ol start="3" style="list-style-type: decimal">
<li>refitted, IPCW
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
ln(bilirubin (mg/dl))
</td>
<td style="text-align:center;">
0.22 (0.04)
</td>
<td style="text-align:center;">
0.92 (0.04)
</td>
<td style="text-align:center;">
0.97 (0.04)
</td>
</tr>
<tr>
<td style="text-align:left;">
ln(creatinine<span class="math inline">\(^1\)</span> (mg/dl))
</td>
<td style="text-align:center;">
0.40 (0.08)
</td>
<td style="text-align:center;">
2.07 (0.08)
</td>
<td style="text-align:center;">
2.15 (0.08)
</td>
</tr>
<tr>
<td style="text-align:left;">
ln(INR)
</td>
<td style="text-align:center;">
0.04 (0.13)
</td>
<td style="text-align:center;">
2.06 (0.13)
</td>
<td style="text-align:center;">
2.22 (0.15)
</td>
</tr>
<tr>
<td style="text-align:left;">
biweekly dialysis
</td>
<td style="text-align:center;">
</td>
<td style="text-align:center;">
1.87 (0.12)
</td>
<td style="text-align:center;">
1.86 (0.12)
</td>
</tr>
<tr>
<td style="text-align:left;">
LR Test
</td>
<td style="text-align:center;">
801 (df = 3)
</td>
<td style="text-align:center;">
22 197 (df = 4)
</td>
<td style="text-align:center;">
26 933 (df = 4)
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup>1</sup> set to 1.0 mg/dl in case of biweekly dialysis
</td>
</tr>
</tfoot>
</table>
</li>
</ol></li>
</ol></li>
</ol></li>
</ol></li>
</ol></li>
</ol>
<table>
<caption>
<span id="tab:ch3tab2relweights">Table 3.4: </span>Relative weights put on bilirubin, creatinine and INR by UNOS-MELD, ReMELD and DynReMELD. Relative weights were calculated <span class="math inline">\(w_{i} = \frac{\beta_{i}\text{SD}_{i}}{\sum_{j}^{}{\beta_{j}\text{SD}_{j}}}\)</span>, where <span class="math inline">\(\beta_{i}\)</span> is the coefficient on biomarker <span class="math inline">\(i\)</span> and <span class="math inline">\(\text{SD}_{i}\)</span> its standard deviation in the development cohort.
</caption>
<thead>
<tr>
<th style="text-align:left;">
biomarker
</th>
<th style="text-align:center;">
standard deviation
</th>
<th style="text-align:center;">
UNOS-MELD
</th>
<th style="text-align:center;">
ReMELD
</th>
<th style="text-align:center;">
DynReMELD
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
bilirubin (mg/dl)
</td>
<td style="text-align:center;">
0.85
</td>
<td style="text-align:center;">
0.36
</td>
<td style="text-align:center;">
0.37
</td>
<td style="text-align:center;">
0.41
</td>
</tr>
<tr>
<td style="text-align:left;">
creatinine (mg/dl)
</td>
<td style="text-align:center;">
0.29
</td>
<td style="text-align:center;">
0.32
</td>
<td style="text-align:center;">
0.29
</td>
<td style="text-align:center;">
0.31
</td>
</tr>
<tr>
<td style="text-align:left;">
INR
</td>
<td style="text-align:center;">
0.26
</td>
<td style="text-align:center;">
0.32
</td>
<td style="text-align:center;">
0.34
</td>
<td style="text-align:center;">
0.28
</td>
</tr>
</tbody>
</table>
</div>
</div>
<div id="definition-of-the-dynremeld-score" class="section level3 hasAnchor" number="3.3.3">
<h3><span class="header-section-number">3.3.3</span> Definition of the DynReMELD score<a href="CHdynremeld.html#definition-of-the-dynremeld-score" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Quantile matching of UNOS-MELD to the linear predictor revised <em>“from
cross-section”</em> with IPCW (Table <a href="CHdynremeld.html#tab:ch3tab2">3.3</a>, panel B) yielded the following
equation for <em>DynReMELD:</em>
<span class="math display">\[
4.14 \ln(\text{bilirubin}) + 9.12 \ln(\text{creatinine}) + 9.42 \ln(\text{INR}) + 8.50
\]</span>
with creatinine bounded between 0.8 and 2.5 mg/dl, bilirubin between 0.6 and 55 mg/dl, and
the INR between 1.0 and 3.0. We calculate DynReMELD scores by setting
creatinine to the upper cap (2.5 mg/dl) for patients on dialysis. This choice
was made to keep DynReMELD in line with existing clinical implementations of
MELD, and is relatively harmless because the creatinine level required
to attain the same priority as biweekly dialysis is
<span class="math inline">\(\exp\left( \frac{1.86}{2.15} \right)\  \approx 2.4\ \)</span>mg/dl (Table <a href="CHdynremeld.html#tab:ch3tab2">3.3</a>,
Panel B, third column).</p>
<p></p>
</div>
<div id="predictive-performance" class="section level3 hasAnchor" number="3.3.4">
<h3><span class="header-section-number">3.3.4</span> Predictive performance<a href="CHdynremeld.html#predictive-performance" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>Table <a href="CHdynremeld.html#tab:ch3tab3">3.5</a> shows estimates of Gerd’s c-index for UNOS-MELD, ReMELD
and DynReMELD, for (a) predicting 90-day waiting list survival from listing
based on biomarkers reported at listing, and (b) predicting 90-day
waiting list survival from calendar-time cross-sections based on the biomarkers
that were last reported for the candidate. The first panel shows c-indices evaluated for predicting 90-day waiting list
survival from listing based on biomarkers reported at listing for
UNOS-MELD, ReMELD and DynReMELD. Point estimates appear to slightly
favor DynReMELD, but bootstrapped pairwise differences are not
statistically significant. The second panel shows that DynReMELD
outperforms UNOS-MELD and ReMELD when predicting 90-day waiting list
survival based on candidates’ last reported biomarkers, with DynReMELD
attaining higher c-indices (p &lt; 0.001) in both development and
validation cohorts. In the validation cohort, the c-index of DynReMELD
(0.7895) is approximately 0.0040 higher than UNOS-MELD (0.7855), and
0.0015 higher than ReMELD (0.7879).</p>
<p></p>

<table class="table" style="margin-left: auto; margin-right: auto;">
<caption>
<span id="tab:ch3tab3">Table 3.5: </span>C-indices at 90 days after listing with bootstrapped standard errors shown in brackets.
</caption>
<thead>
<tr>
<th style="text-align:left;">
score
</th>
<th style="text-align:left;">
development
</th>
<th style="text-align:left;">
validation
</th>
</tr>
</thead>
<tbody>
<tr grouplength="3">
<td colspan="3" style="border-bottom: 1px solid;">
<strong>time-until-death from listing, based on biomarkers at listing</strong>
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;" indentlevel="1">
UNOS-MELD
</td>
<td style="text-align:left;">
0.8494 (0.008)
</td>
<td style="text-align:left;">
0.8637 (0.011)
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;" indentlevel="1">
ReMELD
</td>
<td style="text-align:left;">
0.8503 (0.008)
</td>
<td style="text-align:left;">
0.8623 (0.011)
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;" indentlevel="1">
DynReMELD
</td>
<td style="text-align:left;">
0.8523† (0.008)
</td>
<td style="text-align:left;">
0.8641 (0.011)
</td>
</tr>
<tr grouplength="3">
<td colspan="3" style="border-bottom: 1px solid;">
<strong>remaining time-until-death from cross-sections, based on last reported biomarkers</strong>
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;" indentlevel="1">
UNOS-MELD
</td>
<td style="text-align:left;">
0.8099 (0.002)
</td>
<td style="text-align:left;">
0.7855 (0.004)
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;" indentlevel="1">
ReMELD
</td>
<td style="text-align:left;">
0.8203*** (0.002)
</td>
<td style="text-align:left;">
0.7879 (0.004)
</td>
</tr>
<tr>
<td style="text-align:left;padding-left: 2em;" indentlevel="1">
DynReMELD
</td>
<td style="text-align:left;">
0.8217***††† (0.002)
</td>
<td style="text-align:left;">
0.7895***†† (0.004)
</td>
</tr>
</tbody>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup></sup> <sup>†</sup> p &lt; 0.05, <sup>††</sup> p &lt; 0.01, <sup>†††</sup> p &lt; 0.001, compared to ReMELD
</td>
</tr>
</tfoot>
<tfoot>
<tr>
<td style="padding: 0; border:0;" colspan="100%">
<sup></sup> <sup>∗</sup> p &lt; 0.05, <sup>∗∗</sup> p &lt; 0.01, <sup>∗∗∗</sup> p &lt; 0.001, compared to UNOS-MELD
</td>
</tr>
</tfoot>
</table>
<p></p>
<p></p>
</div>
<div id="estimated-absolute-survival-risk-per-meld-score" class="section level3 hasAnchor" number="3.3.5">
<h3><span class="header-section-number">3.3.5</span> Estimated absolute survival risk per MELD Score<a href="CHdynremeld.html#estimated-absolute-survival-risk-per-meld-score" class="anchor-section" aria-label="Anchor link to header"></a></h3>
<p>This section reports absolute 90-day mortality risks for UNOS-MELD and
DynReMELD estimated <em>“from cross-section”</em>. The estimation of mortality
risks <em>“from cross-section”</em> is complicated by the fact that most
individuals contribute multiple, correlated observations to the Cox
model. In principle, this dependence can be broken by reporting cross-section-specific estimates of 90-day waiting list survival, but such estimates are
imprecise. To partially break the dependence, we chose to estimate
90-day survival on a data set that included, for each reported set of
biomarkers, only the first cross-section where the patient had an active
waiting list status. Table <a href="CHdynremeld.html#tab:ch3tab4">3.6</a> shows 90-day
mortality risks estimated in this way.</p>
<p>The table shows that inverse probability censoring weighting increases
estimates of absolute 90-day mortality risks by almost 10 percentage
points. Failing to correct for informative censoring therefore results in
mortality equivalents that understate the counterfactual mortality
risk. This is of interest to Eurotransplant, as these mortality equivalents
are used by Eurotransplant to assign exception points.</p>
<p>Candidates with multiple sets of biomarkers still contribute multiple observations
to estimating 90-day mortality risks <em>from cross-section</em>. Dependence between
such observations can bias estimates of the 90-day mortality risks. It is reassuring
that point estimates of 90-day mortality risks <em>from registration</em>
(see Table <a href="CHdynremeld.html#tab:ch3stab3">3.7</a>) are close to estimates <em>from
cross-section</em> (generally less than 5 percentage point differences are
observed).</p>
<table class="table table-striped" style="margin-left: auto; margin-right: auto;">
<caption>
<span id="tab:ch3tab4">Table 3.6: </span>The 90-day mortality equivalents that are used by Eurotransplant, as well as estimates of the 90-day mortality risk per score. These were estimated with Cox models fitted “from cross-section”, with adjustment for the MELD point score.
</caption>
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
UNOS-MELD
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
DynReMELD
</div>
</th>
</tr>
<tr>
<th style="text-align:left;">
score
</th>
<th style="text-align:center;">
no IPCW
</th>
<th style="text-align:center;">
IPCW
</th>
<th style="text-align:center;">
no IPCW
</th>
<th style="text-align:center;">
IPCW
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:left;">
20
</td>
<td style="text-align:center;">
0.103 [0.098-0.108]
</td>
<td style="text-align:center;">
0.122 [0.117-0.127]
</td>
<td style="text-align:center;">
0.097 [0.092-0.101]
</td>
<td style="text-align:center;">
0.113 [0.108-0.118]
</td>
</tr>
<tr>
<td style="text-align:left;">
22
</td>
<td style="text-align:center;">
0.149 [0.142-0.155]
</td>
<td style="text-align:center;">
0.179 [0.171-0.186]
</td>
<td style="text-align:center;">
0.145 [0.139-0.151]
</td>
<td style="text-align:center;">
0.173 [0.166-0.180]
</td>
</tr>
<tr>
<td style="text-align:left;">
24
</td>
<td style="text-align:center;">
0.212 [0.202-0.221]
</td>
<td style="text-align:center;">
0.258 [0.247-0.270]
</td>
<td style="text-align:center;">
0.214 [0.205-0.224]
</td>
<td style="text-align:center;">
0.260 [0.249-0.271]
</td>
</tr>
<tr>
<td style="text-align:left;">
25
</td>
<td style="text-align:center;">
0.251 [0.239-0.263]
</td>
<td style="text-align:center;">
0.308 [0.294-0.322]
</td>
<td style="text-align:center;">
0.259 [0.247-0.271]
</td>
<td style="text-align:center;">
0.315 [0.301-0.329]
</td>
</tr>
<tr>
<td style="text-align:left;">
26
</td>
<td style="text-align:center;">
0.297 [0.282-0.311]
</td>
<td style="text-align:center;">
0.365 [0.348-0.382]
</td>
<td style="text-align:center;">
0.310 [0.295-0.325]
</td>
<td style="text-align:center;">
0.379 [0.361-0.396]
</td>
</tr>
<tr>
<td style="text-align:left;">
28
</td>
<td style="text-align:center;">
0.407 [0.385-0.428]
</td>
<td style="text-align:center;">
0.498 [0.473-0.522]
</td>
<td style="text-align:center;">
0.435 [0.413-0.457]
</td>
<td style="text-align:center;">
0.529 [0.503-0.553]
</td>
</tr>
<tr>
<td style="text-align:left;">
29
</td>
<td style="text-align:center;">
0.470 [0.444-0.495]
</td>
<td style="text-align:center;">
0.572 [0.544-0.599]
</td>
<td style="text-align:center;">
0.508 [0.482-0.533]
</td>
<td style="text-align:center;">
0.612 [0.583-0.639]
</td>
</tr>
<tr>
<td style="text-align:left;">
30
</td>
<td style="text-align:center;">
0.538 [0.508-0.566]
</td>
<td style="text-align:center;">
0.649 [0.617-0.678]
</td>
<td style="text-align:center;">
0.585 [0.555-0.613]
</td>
<td style="text-align:center;">
0.696 [0.664-0.725]
</td>
</tr>
<tr>
<td style="text-align:left;">
31
</td>
<td style="text-align:center;">
0.609 [0.576-0.640]
</td>
<td style="text-align:center;">
0.725 [0.691-0.755]
</td>
<td style="text-align:center;">
0.664 [0.632-0.694]
</td>
<td style="text-align:center;">
0.777 [0.744-0.805]
</td>
</tr>
<tr>
<td style="text-align:left;">
32
</td>
<td style="text-align:center;">
0.681 [0.645-0.714]
</td>
<td style="text-align:center;">
0.796 [0.762-0.825]
</td>
<td style="text-align:center;">
0.742 [0.708-0.772]
</td>
<td style="text-align:center;">
0.848 [0.817-0.874]
</td>
</tr>
<tr>
<td style="text-align:left;">
33
</td>
<td style="text-align:center;">
0.751 [0.714-0.784]
</td>
<td style="text-align:center;">
0.859 [0.827-0.885]
</td>
<td style="text-align:center;">
0.814 [0.780-0.842]
</td>
<td style="text-align:center;">
0.907 [0.880-0.927]
</td>
</tr>
<tr>
<td style="text-align:left;">
34
</td>
<td style="text-align:center;">
0.816 [0.780-0.846]
</td>
<td style="text-align:center;">
0.910 [0.883-0.931]
</td>
<td style="text-align:center;">
0.875 [0.845-0.900]
</td>
<td style="text-align:center;">
0.949 [0.929-0.964]
</td>
</tr>
<tr>
<td style="text-align:left;">
35
</td>
<td style="text-align:center;">
0.872 [0.839-0.899]
</td>
<td style="text-align:center;">
0.949 [0.927-0.964]
</td>
<td style="text-align:center;">
0.925 [0.899-0.943]
</td>
<td style="text-align:center;">
0.977 [0.963-0.985]
</td>
</tr>
<tr>
<td style="text-align:left;">
36
</td>
<td style="text-align:center;">
0.918 [0.890-0.940]
</td>
<td style="text-align:center;">
0.974 [0.960-0.984]
</td>
<td style="text-align:center;">
0.959 [0.941-0.972]
</td>
<td style="text-align:center;">
0.991 [0.984-0.995]
</td>
</tr>
<tr>
<td style="text-align:left;">
37
</td>
<td style="text-align:center;">
0.953 [0.930-0.968]
</td>
<td style="text-align:center;">
0.989 [0.980-0.994]
</td>
<td style="text-align:center;">
0.981 [0.969-0.989]
</td>
<td style="text-align:center;">
0.997 [0.994-0.999]
</td>
</tr>
<tr>
<td style="text-align:left;">
39
</td>
<td style="text-align:center;">
0.989 [0.979-0.994]
</td>
<td style="text-align:center;">
0.999 [0.997-1.000]
</td>
<td style="text-align:center;">
0.998 [0.995-0.999]
</td>
<td style="text-align:center;">
1.000 [1.000-1.000]
</td>
</tr>
<tr>
<td style="text-align:left;">
40
</td>
<td style="text-align:center;">
0.996 [0.991-0.998]
</td>
<td style="text-align:center;">
1.000 [0.999-1.000]
</td>
<td style="text-align:center;">
0.999 [0.998-1.000]
</td>
<td style="text-align:center;">
1.000 [1.000-1.000]
</td>
</tr>
</tbody>
</table>
<table class="table table-striped" style="margin-left: auto; margin-right: auto;">
<caption>
<span id="tab:ch3stab3">Table 3.7: </span>Estimates of absolute 90-day mortality risks “from registration” and “from cross-section”. Reported risks were estimated without IPCW.
</caption>
<thead>
<tr>
<th style="empty-cells: hide;border-bottom:hidden;" colspan="1">
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
UNOS-MELD
</div>
</th>
<th style="border-bottom:hidden;padding-bottom:0; padding-left:3px;padding-right:3px;text-align: center; " colspan="2">
<div style="border-bottom: 1px solid #ddd; padding-bottom: 5px; ">
DynReMELD
</div>
</th>
</tr>
<tr>
<th style="text-align:center;">
score
</th>
<th style="text-align:center;">
from cross-section
</th>
<th style="text-align:center;">
from registration
</th>
<th style="text-align:center;">
from cross-section
</th>
<th style="text-align:center;">
from registration
</th>
</tr>
</thead>
<tbody>
<tr>
<td style="text-align:center;">
20
</td>
<td style="text-align:center;">
0.103 [0.098-0.108]
</td>
<td style="text-align:center;">
0.136 [0.127-0.144]
</td>
<td style="text-align:center;">
0.097 [0.092-0.101]
</td>
<td style="text-align:center;">
0.125 [0.116-0.132]
</td>
</tr>
<tr>
<td style="text-align:center;">
22
</td>
<td style="text-align:center;">
0.149 [0.142-0.155]
</td>
<td style="text-align:center;">
0.187 [0.176-0.197]
</td>
<td style="text-align:center;">
0.145 [0.139-0.151]
</td>
<td style="text-align:center;">
0.176 [0.166-0.186]
</td>
</tr>
<tr>
<td style="text-align:center;">
24
</td>
<td style="text-align:center;">
0.212 [0.202-0.221]
</td>
<td style="text-align:center;">
0.254 [0.240-0.267]
</td>
<td style="text-align:center;">
0.214 [0.205-0.224]
</td>
<td style="text-align:center;">
0.247 [0.233-0.260]
</td>
</tr>
<tr>
<td style="text-align:center;">
26
</td>
<td style="text-align:center;">
0.297 [0.282-0.311]
</td>
<td style="text-align:center;">
0.339 [0.321-0.356]
</td>
<td style="text-align:center;">
0.310 [0.295-0.325]
</td>
<td style="text-align:center;">
0.339 [0.321-0.356]
</td>
</tr>
<tr>
<td style="text-align:center;">
28
</td>
<td style="text-align:center;">
0.407 [0.385-0.428]
</td>
<td style="text-align:center;">
0.443 [0.420-0.466]
</td>
<td style="text-align:center;">
0.435 [0.413-0.457]
</td>
<td style="text-align:center;">
0.453 [0.429-0.476]
</td>
</tr>
<tr>
<td style="text-align:center;">
30
</td>
<td style="text-align:center;">
0.538 [0.508-0.566]
</td>
<td style="text-align:center;">
0.564 [0.535-0.591]
</td>
<td style="text-align:center;">
0.585 [0.555-0.613]
</td>
<td style="text-align:center;">
0.586 [0.556-0.613]
</td>
</tr>
<tr>
<td style="text-align:center;">
32
</td>
<td style="text-align:center;">
0.681 [0.645-0.714]
</td>
<td style="text-align:center;">
0.691 [0.657-0.721]
</td>
<td style="text-align:center;">
0.742 [0.708-0.772]
</td>
<td style="text-align:center;">
0.724 [0.690-0.753]
</td>
</tr>
<tr>
<td style="text-align:center;">
34
</td>
<td style="text-align:center;">
0.816 [0.780-0.846]
</td>
<td style="text-align:center;">
0.810 [0.776-0.839]
</td>
<td style="text-align:center;">
0.875 [0.845-0.900]
</td>
<td style="text-align:center;">
0.847 [0.815-0.873]
</td>
</tr>
<tr>
<td style="text-align:center;">
36
</td>
<td style="text-align:center;">
0.918 [0.890-0.940]
</td>
<td style="text-align:center;">
0.905 [0.877-0.927]
</td>
<td style="text-align:center;">
0.959 [0.941-0.972]
</td>
<td style="text-align:center;">
0.935 [0.912-0.953]
</td>
</tr>
<tr>
<td style="text-align:center;">
40
</td>
<td style="text-align:center;">
0.996 [0.991-0.998]
</td>
<td style="text-align:center;">
0.991 [0.983-0.995]
</td>
<td style="text-align:center;">
0.999 [0.998-1.000]
</td>
<td style="text-align:center;">
0.997 [0.993-0.999]
</td>
</tr>
</tbody>
</table>
<p></p>
</div>
</div>
<div id="discussion" class="section level2 hasAnchor" number="3.4">
<h2><span class="header-section-number">3.4</span> Discussion<a href="CHdynremeld.html#discussion" class="anchor-section" aria-label="Anchor link to header"></a></h2>
<p>Prior literature revised the MELD score with liver waiting list candidate data <em>“from
registration”</em> (e.g., <span class="citation"><a href="#ref-kimMELD3point0">[20]</a>, <a href="#ref-kimHyponatremiaMortalityPatients2008a">[37]</a>, <a href="#ref-goudsmitRefittingModelEndstage2020">[42]</a></span>), which ignores any
MELD biomarker measurements that are reported after registration and any
waiting list death that occurs more than 90 days after registration. We used methodology proposed
by Gong and Schaubel <span class="citation"><a href="#ref-gongPartlyConditionalEstimation2013">[57]</a></span> to model waiting list
mortality from calendar-time cross-sections, which can avoid such waste of statistical
information in revising MELD. Moreover, we assessed how revision of MELD
was affected by correction for selection bias by transplantation or delisting with inverse
probability censoring weighting.</p>
<p>We showed that the <em>“from cross-section”</em> approach uses waiting list
registry data substantially more efficiently, with the number of
waiting list deaths and MELD scores informing revision of MELD increasing
sevenfold compared to revision <em>“from registration”</em>. DynReMELD, the
score obtained by quantile matching UNOS-MELD to the risk equation that
was developed <em>“from cross-section”</em> with IPCW, attains significantly higher
c-indices than ReMELD and UNOS-MELD in a geographical validation cohort
for predicting remaining time-until-death based on last reported MELD
biomarkers (p &lt; 0.001). This is important for Eurotransplant, as
Eurotransplant liver allocation prioritizes candidates based on their
last reported MELD scores and not MELD at listing. In magnitude,
the improvements in c-indices (0.0015 compared to ReMELD, and 0.0040
compared to UNOS-MELD) are comparable to the addition of serum sodium to
ReMELD (approx. delta c-index of 0.0030)
<span class="citation"><a href="#ref-goudsmitRefittingModelEndstage2020">[42]</a></span> and the addition of serum albumin to
MELD 3.0 (delta c-index of 0.0028) <span class="citation"><a href="#ref-kimMELD3point0">[20]</a></span>. MELD revision from
cross-section with IPCW can thus improve urgency-based risk
stratification. Our results suggest that the improvement is due to
modeling time-remaining-until-death from cross-sections and not IPCW,
as IPCW changed estimated coefficients only slightly.</p>
<p>We believe the main reason why DynReMELD outperforms ReMELD in
geographical validation is that revision <em>“from cross-section”</em> uses Eurotransplant
registry data substantially more efficiently than revision <em>“from
registration”</em>, as the latter method only uses the MELD biomarkers that were reported
at listing and the first 90 days of waiting list survival. This raises the
question whether revision <em>“from registration”</em> cannot also be improved
upon by using available registry data more efficiently. One way of doing
this would be to include MELD biomarkers as time-varying covariates. However,
because MELD biomarkers also increase inherently as part of the death process,
use of biomarkers as time-varying covariates leads to issues of reverse causality. Follow-up data could,
in principle, also be used more efficiently by not restricting revision <em>“from
registration”</em> to the first 90 days after listing. However, we found
that this leads to violations of the proportional hazards assumption for
MELD biomarkers.
We also assessed how estimates of the 90-day mortality risks are affected
by (a) revision <em>“from cross-section”</em> and (b) correcting for dependent
censoring with IPCW. Revision <em>“from cross-section”</em> does not
meaningfully change estimated 90-day mortality risks, with risks
estimated <em>“from cross-section”</em> differing by less than 5 percent points
from risks estimated <em>“from registration”</em>. This means that we do not
find that there are meaningful differences in 90-day mortality risks between
a candidate who reported a particular MELD score at listing and another
one who reported that same score as part of a MELD
recertification. Mitigation of selection bias with IPCW did increase
estimated 90-day waiting list mortality risks for both UNOS-MELD and
DynReMELD by 10 percentage points. Failure to account for informative censoring by transplantation/delisting thus leads to an underestimation of
90-day mortality equivalents, which can be problematic as Eurotransplant uses
these estimates to assign MELD scores for candidates who receive exception points.</p>
<p>Eurotransplant currently consists of 38 liver transplant centers
located in seven European countries. These centers differ structurally in
terms of patient populations, liver transplantation volumes, and willingness to accept
donors of marginal quality. A strength of our study is that we assigned
candidates to either the development or validation cohort based on their
center of listing, which means that the predictive performance of
DynReMELD was evaluated in a cohort independent from the centers on
which the score was developed.</p>
<p>A limitation of our work is that revision of MELD <em>“from cross-section”</em>
only uses the last MELD biomarkers reported before the cross-section date.
Eurotransplant
uses these same biomarker measurements for allocation, but they may be outdated
representations of a patient’s health status. Alternatively, one could
model the evolution of MELD biomarkers over time with linear mixed
models, and use a best linear unbiased
predictions (BLUP) of biomarkers at every cross-section time. This BLUP
approach was first proposed by Maziarz et al.
<span class="citation"><a href="#ref-maziarzLongitudinalPredictionTimetoEvent2017">[63]</a></span> for landmarking, a
statistical technique which bears similarities to Gong and Schaubel’s
approach. We did not use a BLUP approach to revise MELD, since irregular
spacing of MELD measurements complicates modeling the biomarker process. Deployment of BLUP models would also be practically challenging for
Eurotransplant. Moreover, MELD scores for patients with significant
90-day mortality risks are rarely outdated as Eurotransplant requires
frequent re-certification of MELD scores for sicker patients. For example,
MELD scores are on average 12 days old at cross-section for candidates with
MELD scores ranging between 20 and 25
(corresponding to a 90-day mortality risk of 10 to 25%), and 3 days
old for MELD scores greater than 25 (which corresponds to a mortality risk of
25% or greater).
A final limitation of our work is that DynReMELD was based only on
bilirubin, creatinine and the INR, while updated versions of MELD exist that
use additional biomarkers. Future work could focus on revising these UNOS-MELD
alternatives <em>“from cross-section”</em>. This was not pursued in this chapter,
because serum sodium and albumin are unavailable in Eurotransplant registry data
for most patients on the liver waiting list.</p>
<p></p>

</div>
</div>
<h3>References</h3>
<div id="refs" class="references csl-bib-body" entry-spacing="0">
<div id="ref-kimMELD3point0" class="csl-entry">
<div class="csl-left-margin">[20] </div><div class="csl-right-inline">W. R. Kim <em>et al.</em>, <span>“<span>MELD</span> 3.0: The <span class="nocase">Model for End-Stage Liver Disease</span> updated for the modern era,”</span> <em>Gastroenterology</em>, vol. 161, no. 6, pp. 1887–1895.e4, 2021, doi: <a href="https://doi.org/10.1053/j.gastro.2021.08.050">10.1053/j.gastro.2021.08.050</a>.</div>
</div>
<div id="ref-malinchocModelPredictPoor2000" class="csl-entry">
<div class="csl-left-margin">[33] </div><div class="csl-right-inline">M. Malinchoc, P. S. Kamath, F. D. Gordon, C. J. Peine, J. Rank, and P. C. J. ter Borg, <span>“A model to predict poor survival in patients undergoing transjugular intrahepatic portosystemic shunts,”</span> <em>Hepatology</em>, vol. 31, no. 4, pp. 864–871, 2000, doi: <a href="https://doi.org/10.1053/he.2000.5852">10.1053/he.2000.5852</a>.</div>
</div>
<div id="ref-kimHyponatremiaMortalityPatients2008a" class="csl-entry">
<div class="csl-left-margin">[37] </div><div class="csl-right-inline">W. R. Kim <em>et al.</em>, <span>“Hyponatremia and mortality among patients on the liver-transplant waiting list,”</span> <em>The New England Journal of Medicine</em>, vol. 359, no. 10, pp. 1018–1026, 2008, doi: <a href="https://doi.org/10.1056/NEJMoa0801209">10.1056/NEJMoa0801209</a>.</div>
</div>
<div id="ref-merionLongitudinalAssessmentMortality2003" class="csl-entry">
<div class="csl-left-margin">[39] </div><div class="csl-right-inline">R. Merion, <span>“Longitudinal assessment of mortality risk among candidates for liver transplantation,”</span> <em>Liver Transplantation</em>, vol. 9, no. 1, pp. 12–18, 2003, doi: <a href="https://doi.org/10.1053/jlts.2003.50009">10.1053/jlts.2003.50009</a>.</div>
</div>
<div id="ref-sharmaReweightingModelEndStage2008" class="csl-entry">
<div class="csl-left-margin">[40] </div><div class="csl-right-inline">P. Sharma, D. E. Schaubel, C. S. Sima, R. M. Merion, and A. S. F. Lok, <span>“Re-weighting the <span class="nocase">Model for End-Stage Liver Disease</span> score components,”</span> <em>Gastroenterology</em>, vol. 135, no. 5, pp. 1575–1581, 2008, doi: <a href="https://doi.org/10.1053/j.gastro.2008.08.004">10.1053/j.gastro.2008.08.004</a>.</div>
</div>
<div id="ref-leiseRevisedModelEndstage2011" class="csl-entry">
<div class="csl-left-margin">[41] </div><div class="csl-right-inline">M. D. Leise, W. R. Kim, W. K. Kremers, J. J. Larson, J. T. Benson, and T. M. Therneau, <span>“A revised <span class="nocase">Model for End-Stage Liver Disease</span> optimizes prediction of mortality among patients awaiting liver transplantation,”</span> <em>Gastroenterology</em>, vol. 140, no. 7, pp. 1952–1960, 2011, doi: <a href="https://doi.org/10.1053/j.gastro.2011.02.017">10.1053/j.gastro.2011.02.017</a>.</div>
</div>
<div id="ref-goudsmitRefittingModelEndstage2020" class="csl-entry">
<div class="csl-left-margin">[42] </div><div class="csl-right-inline">B. F. J. Goudsmit <em>et al.</em>, <span>“Refitting the <span class="nocase">Model for End-Stage Liver Disease</span> for the <span>Eurotransplant</span> region,”</span> <em>Hepatology</em>, 2020, doi: <a href="https://doi.org/10.1002/hep.31677">10.1002/hep.31677</a>.</div>
</div>
<div id="ref-deFerranteDynremeld" class="csl-entry">
<div class="csl-left-margin">[55] </div><div class="csl-right-inline">H. C. de Ferrante, M. van Rosmalen, B. M. L. Smeulders, S. Vogelaar, and F. C. R. Spieksma, <span>“Revising <span class="nocase">Model for End-Stage Liver Disease</span> from calendar-time cross-sections with correction for selection bias,”</span> <em>BMC Medical Research Methodology</em>, vol. 24, no. 1, 2024, doi: <a href="https://doi.org/10.1186/s12874-024-02176-8">10.1186/s12874-024-02176-8</a>.</div>
</div>
<div id="ref-bambhaPredictingSurvivalPatients2004" class="csl-entry">
<div class="csl-left-margin">[56] </div><div class="csl-right-inline">K. Bambha <em>et al.</em>, <span>“Predicting survival among patients listed for liver transplantation: An assessment of serial <span>MELD</span> measurements,”</span> <em>American Journal of Transplantation</em>, vol. 4, no. 11, pp. 1798–1804, 2004, doi: <a href="https://doi.org/10.1111/j.1600-6143.2004.00550.x">10.1111/j.1600-6143.2004.00550.x</a>.</div>
</div>
<div id="ref-gongPartlyConditionalEstimation2013" class="csl-entry">
<div class="csl-left-margin">[57] </div><div class="csl-right-inline">Q. Gong and D. E. Schaubel, <span>“Partly conditional estimation of the effect of a time-dependent factor in the presence of dependent censoring,”</span> <em>Biometrics</em>, vol. 69, no. 2, pp. 338–347, 2013, doi: <a href="https://doi.org/10.1111/biom.12023">10.1111/biom.12023</a>.</div>
</div>
<div id="ref-ETLiverMan2025" class="csl-entry">
<div class="csl-left-margin">[58] </div><div class="csl-right-inline">Eurotransplant, <span>“<span>Eurotransplant Manual</span> manual. Chapter 4: <span>ET Liver Allocation System (ELAS)</span>.”</span> Available: <a href="https://www.eurotransplant.org/allocation/eurotransplant-manual/">https://www.eurotransplant.org/allocation/eurotransplant-manual/</a></div>
</div>
<div id="ref-schnellingerMitigatingSelectionBias2021" class="csl-entry">
<div class="csl-left-margin">[59] </div><div class="csl-right-inline">E. M. Schnellinger, E. Cantu, M. O. Harhay, D. E. Schaubel, S. E. Kimmel, and A. J. Stephens-Shields, <span>“Mitigating selection bias in organ allocation models,”</span> <em>BMC Medical Research Methodology</em>, vol. 21, no. 1, 2021, doi: <a href="https://doi.org/10.1186/s12874-021-01379-7">10.1186/s12874-021-01379-7</a>.</div>
</div>
<div id="ref-gerdsEstimatingTimedependentConcordance2012" class="csl-entry">
<div class="csl-left-margin">[60] </div><div class="csl-right-inline">T. A. Gerds, M. W. Kattan, M. Schumacher, and C. Yu, <span>“Estimating a time-dependent concordance index for survival prediction models with covariate dependent censoring,”</span> <em>Statistics in Medicine</em>, vol. 32, no. 13, pp. 2173–2184, 2012, doi: <a href="https://doi.org/10.1002/sim.5681">10.1002/sim.5681</a>.</div>
</div>
<div id="ref-Hartman2025" class="csl-entry">
<div class="csl-left-margin">[61] </div><div class="csl-right-inline">N. Hartman, <span>“Concordance indices for risk scores with policy evaluations,”</span> <em>Health Services Research</em>, 2025, doi: <a href="https://doi.org/10.1111/1475-6773.14619">10.1111/1475-6773.14619</a>.</div>
</div>
<div id="ref-linScopingReviewCausal2021" class="csl-entry">
<div class="csl-left-margin">[62] </div><div class="csl-right-inline">L. Lin, M. Sperrin, D. A. Jenkins, G. P. Martin, and N. Peek, <span>“A scoping review of causal methods enabling predictions under hypothetical interventions,”</span> <em>Diagnostic and Prognostic Research</em>, vol. 5, no. 1, 2021, doi: <a href="https://doi.org/10.1186/s41512-021-00092-9">10.1186/s41512-021-00092-9</a>.</div>
</div>
<div id="ref-maziarzLongitudinalPredictionTimetoEvent2017" class="csl-entry">
<div class="csl-left-margin">[63] </div><div class="csl-right-inline">M. Maziarz, P. Heagerty, T. Cai, and Y. Zheng, <span>“On longitudinal prediction with time-to-event outcome: Comparison of modeling options,”</span> <em>Biometrics</em>, vol. 73, no. 1, pp. 83–93, 2017, doi: <a href="https://doi.org/10.1111/biom.12562">10.1111/biom.12562</a>.</div>
</div>
</div>
<div class="footnotes">
<hr />
<ol start="1">
<li id="fn1"><p>A small group of patients is removed from the waiting list without
transplant, but later re-registered.<a href="CHdynremeld.html#fnref1" class="footnote-back">↩︎</a></p></li>
</ol>
</div>
            </section>

          </div>
        </div>
      </div>
<a href="CHprefaceliver.html" class="navigation navigation-prev " aria-label="Previous page"><i class="fa fa-angle-left"></i></a>
<a href="CHsexdisparity.html" class="navigation navigation-next " aria-label="Next page"><i class="fa fa-angle-right"></i></a>
    </div>
  </div>
<script src="libs/gitbook-2.6.7/js/app.min.js"></script>
<script src="libs/gitbook-2.6.7/js/clipboard.min.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-search.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-sharing.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-fontsettings.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-bookdown.js"></script>
<script src="libs/gitbook-2.6.7/js/jquery.highlight.js"></script>
<script src="libs/gitbook-2.6.7/js/plugin-clipboard.js"></script>
<script>
gitbook.require(["gitbook"], function(gitbook) {
gitbook.start({
"sharing": {
"github": false,
"facebook": true,
"twitter": true,
"linkedin": false,
"weibo": false,
"instapaper": false,
"vk": false,
"whatsapp": false,
"all": ["facebook", "twitter", "linkedin", "weibo", "instapaper"]
},
"fontsettings": {
"theme": "white",
"family": "sans",
"size": 2
},
"edit": {
"link": null,
"text": null
},
"history": {
"link": null,
"text": null
},
"view": {
"link": null,
"text": null
},
"download": ["thesis.pdf"],
"search": {
"engine": "fuse",
"options": null
},
"toc": {
"collapse": "subsection"
}
});
});
</script>

<!-- dynamically load mathjax for compatibility with self-contained -->
<script>
  (function () {
    var script = document.createElement("script");
    script.type = "text/javascript";
    var src = "true";
    if (src === "" || src === "true") src = "https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.9/latest.js?config=TeX-MML-AM_CHTML";
    if (location.protocol !== "file:")
      if (/^https?:/.test(src))
        src = src.replace(/^https?:/, '');
    script.src = src;
    document.getElementsByTagName("head")[0].appendChild(script);
  })();
</script>
</body>

</html>
